Gearry RB - Search Results

1

Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.

Swaminathan A, Borichevsky GM, Edwards TS, Hirschfeld E, Mules TC, Frampton CMA, Day AS, Hampton MB, Kettle AJ, Gearry RB. Swaminathan A, et al. Among authors: gearry rb. J Crohns Colitis. 2022 Dec 5;16(12):1862-1873. doi: 10.1093/ecco-jcc/jjac098. J Crohns Colitis. 2022. PMID: 35803583 Free PMC article.

2

Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease.

Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML, Clark DW, Hansen P. Priest VL, et al. Among authors: gearry rb. Pharmacoeconomics. 2006;24(8):767-81. doi: 10.2165/00019053-200624080-00004. Pharmacoeconomics. 2006. PMID: 16898847

3

High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study.

Gearry RB, Richardson A, Frampton CM, Collett JA, Burt MJ, Chapman BA, Barclay ML. Gearry RB, et al. Inflamm Bowel Dis. 2006 Oct;12(10):936-43. doi: 10.1097/01.mib.0000231572.88806.b9. Inflamm Bowel Dis. 2006. PMID: 17012964

4

Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort.

Gearry RB, Roberts RL, Burt MJ, Frampton CM, Chapman BA, Collett JA, Shirley P, Allington MD, Kennedy MA, Barclay ML. Gearry RB, et al. Inflamm Bowel Dis. 2007 Oct;13(10):1220-7. doi: 10.1002/ibd.20190. Inflamm Bowel Dis. 2007. PMID: 17538984

5

Inflammatory bowel disease in New Zealand children--a growing problem.

Gearry RB, Day AS. Gearry RB, et al. N Z Med J. 2008 Oct 3;121(1283):5-8. N Z Med J. 2008. PMID: 18841178 No abstract available.

6

Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype.

Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Tarrant KM, et al. Among authors: gearry rb. Am J Gastroenterol. 2008 Dec;103(12):3082-93. doi: 10.1111/j.1572-0241.2008.02212.x. Am J Gastroenterol. 2008. PMID: 19086959

7

Population-based cases control study of inflammatory bowel disease risk factors.

Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Gearry RB, et al. J Gastroenterol Hepatol. 2010 Feb;25(2):325-33. doi: 10.1111/j.1440-1746.2009.06140.x. Epub 2010 Jan 14. J Gastroenterol Hepatol. 2010. PMID: 20074146

8

Rifaximin and Crohn's disease: a new solution to an old problem?

Day AS, Gearry RB. Day AS, et al. Among authors: gearry rb. Dig Dis Sci. 2010 Apr;55(4):877-9. doi: 10.1007/s10620-010-1140-6. Dig Dis Sci. 2010. PMID: 20155320 No abstract available.

9

New Zealand Society of Gastroenterology statement on the use of biological therapy in inflammatory bowel disease.

Schultz M, Gearry R, Walmsley R, Day AS, Fraser A, Wyeth J, Barclay M, Clover G, Whiteside C. Schultz M, et al. N Z Med J. 2010 May 14;123(1314):134-44. N Z Med J. 2010. PMID: 20590012 Review. No abstract available.

10

SLC11A1 polymorphisms in inflammatory bowel disease and Mycobacterium avium subspecies paratuberculosis status.

Stewart LC, Day AS, Pearson J, Barclay ML, Gearry RB, Roberts RL, Bentley RW. Stewart LC, et al. Among authors: gearry rb. World J Gastroenterol. 2010 Dec 7;16(45):5727-31. doi: 10.3748/wjg.v16.i45.5727. World J Gastroenterol. 2010. PMID: 21128323 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

345 results

Search Page

Filters